Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Euro remains stronger against Canadian Dollar following Eurozone Unemployment Rate

Euro remains stronger against Canadian Dollar following Eurozone Unemployment Rate

FXStreetFXStreet2026/07/02 10:09
By:FXStreet

EUR/CAD rises after two days of losses, trading around 1.6200 during the European hours on Thursday. The pair remains stronger as the Euro (EUR) holds ground following the release of the Eurozone Unemployment Rate, which came in at 6.2% in May, against the 6.3% expected. The previous reading was revised to 6.2% from 6.3%.

Diverging views emerged from European Central Bank (ECB) officials on Wednesday regarding the path of interest rates. Belgian central bank chief Pierre Wunsch stated he does not favor further monetary policy tightening, noting that any inflation surprises ahead of the July meeting are more likely to skew to the downside. Conversely, ECB Governing Council member Martin Kocher suggested that the central bank's next move will either be a rate hike or a hold, warning that rising wages could keep inflationary pressures stubbornly elevated.

The EUR/CAD cross may further appreciate as the commodity-linked Canadian Dollar (CAD) could face challenges amid falling oil prices. Global crude benchmarks have experienced a sharp downturn, sliding significantly below recent highs as supply anxieties begin to ease.

This energy market decline is primarily driven by a rapid recovery in maritime shipping traffic through the critical Strait of Hormuz, coupled with notable breakthroughs in indirect diplomatic talks between Washington and Tehran. While lower energy prices have helped soothe inflation concerns, they simultaneously sap the strength of the petro-dependent CAD.

Statistics Canada indicated earlier this week that the economy grew by 0.5% in April, rebounding more robustly than anticipated following a mild contraction in March. Furthermore, an advance estimate pointing to an additional 0.1% monthly expansion in May suggests that national growth may be stabilizing, a trend that has successfully eased investor fears over a deeper, tariff-driven economic slowdown.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales